Literature DB >> 33643267

AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections.

Rafael Ayerbe-Algaba1,2, Nuria Bayó3, Ester Verdú3, Raquel Parra-Millán1,2, Jesús Seco3, Meritxell Teixidó3, Jerónimo Pachón2,4, Ernest Giralt3,5, Younes Smani1,2.   

Abstract

Previously, we identified that a cyclic hexapeptide AOA-2 inhibited the interaction of Gram-negative bacilli (GNB) like Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli to host cells thereby preventing the development of infection in vitro and in a murine sepsis peritoneal model. In this work, we aimed to evaluate in vitro a library of AOA-2 derivatives in order to improve the effect of AOA-2 against GNB infections. Ten AOA-2 derivatives were synthetized for the in vitro assays. Their toxicities to human lung epithelial cells (A549 cells) for 24 h were evaluated by determining the A549 cells viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The effect of these peptide derivatives and AOA-2 at 250, 125, 62.5, and 31.25 μg/mL on the attachment of A. baumannii ATCC 17978, P. aeruginosa PAO1 and E. coli ATCC 25922 strains to A549 cells was characterized by adherence and viability assays. None of the 10 derivatives showed toxicity to A549 cells. RW01 and RW06 have reduced more the adherence of ATCC 17978, PAO1 and ATCC 2599 strains to A549 cells when compared with the original compound AOA-2. Moreover, both peptides have increased slightly the viability of infected A549 cells by PAO1 and ATCC 25922 than those observed with AOA-2. Finally, RW01 and RW06 have potentiated the activity of colistin against ATCC 17978 strain in the same level with AOA-2. The optimization program of AOA-2 has generated two derivatives (RW01 and RW06) with best effect against interaction of GNB with host cells, specifically against P. aeruginosa and E. coli.
Copyright © 2021 Ayerbe-Algaba, Bayó, Verdú, Parra-Millán, Seco, Teixidó, Pachón, Giralt and Smani.

Entities:  

Keywords:  AOA-2 derivatives; Gram-negative bacilli; inhibitor; outer membrane protein A; peptides

Year:  2021        PMID: 33643267      PMCID: PMC7907166          DOI: 10.3389/fmicb.2021.634323

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  32 in total

1.  Deciphering the roles of outer membrane protein A extracellular loops in the pathogenesis of Escherichia coli K1 meningitis.

Authors:  Rahul Mittal; Subramanian Krishnan; Ignacio Gonzalez-Gomez; Nemani V Prasadarao
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

Review 2.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

3.  Outer membrane protein A (OmpA) contributes to serum resistance and pathogenicity of Escherichia coli K-1.

Authors:  J N Weiser; E C Gotschlich
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

4.  OmpA of uropathogenic Escherichia coli promotes postinvasion pathogenesis of cystitis.

Authors:  Tracy F Nicholson; Kristin M Watts; David A Hunstad
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

5.  Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells.

Authors:  Chul Hee Choi; Eun Young Lee; Yoo Chul Lee; Tae In Park; Hwa Jung Kim; Sung Hee Hyun; Soon Ae Kim; Seong-Kyu Lee; Je Chul Lee
Journal:  Cell Microbiol       Date:  2005-08       Impact factor: 3.715

6.  Outer membrane protein A of Escherichia coli contributes to invasion of brain microvascular endothelial cells.

Authors:  N V Prasadarao; C A Wass; J N Weiser; M F Stins; S H Huang; K S Kim
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

7.  Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.

Authors:  Cassie Jarvis; Zhenfu Han; Vasilios Kalas; Roger Klein; Jerome S Pinkner; Bradley Ford; Jana Binkley; Corinne K Cusumano; Zachary Cusumano; Laurel Mydock-McGrane; Scott J Hultgren; James W Janetka
Journal:  ChemMedChem       Date:  2016-01-26       Impact factor: 3.466

8.  Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: mechanistic analysis and in vivo efficacy.

Authors:  Raquel Parra-Millán; Xavier Vila-Farrés; Rafael Ayerbe-Algaba; Monica Varese; Viviana Sánchez-Encinales; Nuría Bayó; María Eugenia Pachón-Ibáñez; Meritxell Teixidó; Jordi Vila; Jerónimo Pachón; Ernest Giralt; Younes Smani
Journal:  J Antimicrob Chemother       Date:  2018-12-01       Impact factor: 5.790

Review 9.  Pathogenic Escherichia coli.

Authors:  James B Kaper; James P Nataro; Harry L Mobley
Journal:  Nat Rev Microbiol       Date:  2004-02       Impact factor: 60.633

10.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Authors:  Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-21       Impact factor: 71.421

View more
  2 in total

1.  Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.

Authors:  Andrea Miró-Canturri; Andrea Vila-Domínguez; Marta Caretero-Ledesma; Rafael Ayerbe-Algaba; Jerónimo Pachón; Manuel Enrique Jiménez-Mejías; Younes Smani
Journal:  Microbiol Spectr       Date:  2021-10-20

2.  Therapeutic Effects of Inhibitor of ompA Expression against Carbapenem-Resistant Acinetobacter baumannii Strains.

Authors:  Seok-Hyeon Na; Hyejin Jeon; Man-Hwan Oh; Yoo-Jeong Kim; Mingi Chu; Ill-Young Lee; Je-Chul Lee
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.